Versor Investments LP Makes New Investment in CryoPort, Inc. $CYRX

Key Points

• Versor Investments LP has made a new investment in CryoPort, Inc. by purchasing 29,100 shares valued at approximately $177,000, equating to a 0.06% ownership stake.
• Insider transactions show significant sales, with Director Ramkumar Mandalam selling over 40,000 shares, indicating a 30.61% decrease in ownership.
• CryoPort reported a net revenue of $45.45 million for the last quarter, surpassing analyst expectations, although it missed EPS estimates, reporting ($0.29).

Versor Investments LP bought a new stake in CryoPort, Inc. (NASDAQ:CYRX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 29,100 shares of the company's stock, valued at approximately $177,000. Versor Investments LP owned approximately 0.06% of CryoPort as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. raised its holdings in CryoPort by 148.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock worth $28,000 after acquiring an additional 2,120 shares in the last quarter. Lazard Asset Management LLC acquired a new position in shares of CryoPort in the 4th quarter valued at approximately $51,000. SBI Securities Co. Ltd. boosted its stake in CryoPort by 548,750.0% in the first quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company's stock valued at $67,000 after buying an additional 10,975 shares in the last quarter. Quarry LP acquired a new position in shares of CryoPort during the fourth quarter worth $69,000. Finally, CWM LLC lifted its holdings in shares of CryoPort by 1,437.0% during the first quarter. CWM LLC now owns 11,328 shares of the company's stock worth $69,000 after purchasing an additional 10,591 shares during the period. 92.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on CYRX. Leerink Partnrs upgraded CryoPort from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, August 6th. Leerink Partners upgraded CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 target price for the company in a research report on Wednesday, August 6th. BTIG Research reduced their target price on CryoPort from $13.00 to $10.00 and set a "buy" rating on the stock in a report on Monday, July 7th. Morgan Stanley lowered their price objective on CryoPort from $8.00 to $7.00 and set an "equal weight" rating on the stock in a research report on Monday, May 5th. Finally, Stephens initiated coverage on shares of CryoPort in a research report on Tuesday, July 22nd. They set an "overweight" rating and a $13.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $12.00.

Insider Activity

In other CryoPort news, CFO Robert Stefanovich sold 9,300 shares of CryoPort stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $8.67, for a total value of $80,631.00. Following the transaction, the chief financial officer directly owned 207,213 shares of the company's stock, valued at approximately $1,796,536.71. The trade was a 4.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jerrell Shelton sold 16,344 shares of CryoPort stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $7.06, for a total value of $115,388.64. Following the sale, the chief executive officer directly owned 912,419 shares of the company's stock, valued at approximately $6,441,678.14. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 499,747 shares of company stock worth $3,417,829. 10.10% of the stock is currently owned by insiders.

CryoPort Trading Down 0.2%

Shares of NASDAQ CYRX traded down $0.02 during trading hours on Tuesday, hitting $8.79. 252,561 shares of the company traded hands, compared to its average volume of 534,475. The company has a current ratio of 16.24, a quick ratio of 15.47 and a debt-to-equity ratio of 0.39. CryoPort, Inc. has a 12 month low of $4.58 and a 12 month high of $9.48. The stock has a market capitalization of $440.12 million, a price-to-earnings ratio of 6.61 and a beta of 1.88. The company's 50 day moving average price is $7.67 and its 200 day moving average price is $6.66.

CryoPort (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.09). The business had revenue of $45.45 million during the quarter, compared to the consensus estimate of $41.74 million. CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. CryoPort has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.